JP2009513663A5 - - Google Patents

Download PDF

Info

Publication number
JP2009513663A5
JP2009513663A5 JP2008537953A JP2008537953A JP2009513663A5 JP 2009513663 A5 JP2009513663 A5 JP 2009513663A5 JP 2008537953 A JP2008537953 A JP 2008537953A JP 2008537953 A JP2008537953 A JP 2008537953A JP 2009513663 A5 JP2009513663 A5 JP 2009513663A5
Authority
JP
Japan
Prior art keywords
mice
treated
fbn1c1039g
losartan
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008537953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513663A (ja
JP5602365B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/041846 external-priority patent/WO2007050793A2/en
Publication of JP2009513663A publication Critical patent/JP2009513663A/ja
Publication of JP2009513663A5 publication Critical patent/JP2009513663A5/ja
Application granted granted Critical
Publication of JP5602365B2 publication Critical patent/JP5602365B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008537953A 2005-10-25 2006-10-25 マルファン症候群及び関連疾患を治療するための方法及び組成物。 Expired - Fee Related JP5602365B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72997605P 2005-10-25 2005-10-25
US60/729,976 2005-10-25
PCT/US2006/041846 WO2007050793A2 (en) 2005-10-25 2006-10-25 Methods and compositions for the treatment of marfan syndrome and associated disorders

Publications (3)

Publication Number Publication Date
JP2009513663A JP2009513663A (ja) 2009-04-02
JP2009513663A5 true JP2009513663A5 (enExample) 2012-10-04
JP5602365B2 JP5602365B2 (ja) 2014-10-08

Family

ID=37968564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537953A Expired - Fee Related JP5602365B2 (ja) 2005-10-25 2006-10-25 マルファン症候群及び関連疾患を治療するための方法及び組成物。

Country Status (5)

Country Link
US (1) US8597646B2 (enExample)
EP (2) EP2862867A3 (enExample)
JP (1) JP5602365B2 (enExample)
ES (1) ES2526705T3 (enExample)
WO (1) WO2007050793A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5470261B2 (ja) * 2007-11-02 2014-04-16 アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) 大動脈瘤非ヒト動物モデルの作出方法
WO2010123136A1 (en) 2009-04-20 2010-10-28 The University Of Tokyo Association of htra1 mutations and familial ischemic cerebral small-vessel disease
WO2011041545A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
RU2456925C1 (ru) * 2011-03-15 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития идиопатического сколиоза у детей
US20140148498A1 (en) * 2011-04-14 2014-05-29 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2013078261A1 (en) 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
JP6240379B2 (ja) * 2012-10-06 2017-11-29 株式会社 バイオエルティ 循環型TGF−βの抑制剤
MX388059B (es) * 2012-11-06 2025-03-19 Scholar Rock Inc Composiciones y metodos para modular la comunicacion celular.
KR102258457B1 (ko) 2013-03-11 2021-05-31 젠자임 코포레이션 조작된 항-tgf-베타 항체 및 항원-결합 단편
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
BR112015028788A2 (pt) * 2013-05-24 2017-09-19 Tarix Pharmaceuticals Ltd Peptídeos de angiotensina no tratamento da síndrome de marfan e de distúrbios relacionados
SG11201805941WA (en) 2016-02-17 2018-09-27 Novartis Ag Tgfbeta 2 antibodies
US11692028B2 (en) 2017-03-02 2023-07-04 The Johns Hopkins University Map kinase pathway targets for the treatment of Marfan syndrome
EP3675880B1 (en) 2017-09-01 2023-06-07 The Johns Hopkins University Targeted epigenetic therapy for inherited aortic aneurysm condition
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
JP7686069B2 (ja) * 2020-12-23 2025-05-30 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー TGF-βシグナル伝達を抑制できる新規なペプチドおよびその用途
JP2025529287A (ja) * 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
WO2025085731A1 (en) * 2023-10-18 2025-04-24 Children's National Medical Center TRANSFORMING GROWTH FACTOR ß (TGF-ß) OLIGONUCLEOTIDE COMBINATION THERAPY FOR TREATING MUSCULOSKELETAL DISEASES

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
FI906411A7 (fi) 1988-06-28 1990-12-27 La Jolla Cancer Res Foundation Solujen lisääntymisen esto Decorinilla
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0494264B1 (en) 1989-09-29 1997-06-18 La Jolla Cancer Research Foundation Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
CA2068204C (en) 1989-11-22 2002-02-12 Arthur Levinson Latency associated peptides and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ TGF−β型受容体cDNAおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
CA2123418A1 (en) 1991-11-14 1993-05-27 Erkki I. Ruoslahti Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
AU670770B2 (en) 1991-12-04 1996-08-01 La Jolla Cancer Research Foundation Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
AU3920693A (en) 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
AU3943793A (en) 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
JPH08504763A (ja) 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ,インコーポレイテッド 治療薬としてのTGF−βレセプターフラグメントの使用
CA2147754A1 (en) 1992-10-30 1994-05-11 Michelle Letarte Compositions and methods for modifying the regulatory activity of tgf- .beta.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
ATE211762T1 (de) 1993-04-30 2002-01-15 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
ATE208494T1 (de) 1994-05-04 2001-11-15 Mount Sinai Hospital Corp Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5550127A (en) * 1995-09-07 1996-08-27 Pantano; James A. Method of treatment for eiph in racing stock
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997031020A1 (en) 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
CA2232682A1 (en) 1996-04-30 1997-11-06 Susan M. Richards Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
EP0919621B1 (en) 1996-07-24 2008-10-29 Chugai Seiyaku Kabushiki Kaisha Human tak1 and dna encoding the same
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
WO1998007735A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6017755A (en) 1996-08-22 2000-01-25 Hsc Research & Development Limited MADR2 tumour suppressor gene
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
JPH10114676A (ja) * 1996-10-09 1998-05-06 Toray Ind Inc β型トランスフォーミング増殖因子産生抑制剤
WO1998017304A1 (en) 1996-10-25 1998-04-30 Johnson & Johnson Medical, Inc. Anti-fibrotic agent assay
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
TR199902878T2 (xx) 1997-04-18 2000-02-21 Biogen,Inc. Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
JPH10295381A (ja) 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
AU747576B2 (en) 1997-05-20 2002-05-16 Ludwig Institute For Cancer Research Smad7 and uses thereof
US6365711B1 (en) 1997-05-28 2002-04-02 President And Fellows Of Harvard College Methods and reagents for modulating TGF-β superfamily signalling
ATE253636T1 (de) 1997-06-02 2003-11-15 Vlaams Interuniv Inst Biotech Mit smad wechselwirkende polypeptide und verwendungen davon
AU749465B2 (en) 1997-06-13 2002-06-27 Japanese Foundation For Cancer Research Smad6 and uses thereof
AU3365299A (en) 1998-03-27 1999-10-18 Eli Lilly And Company Treatment and prevention of vascular disease
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
JP2003509030A (ja) * 1999-09-17 2003-03-11 アイシス・ファーマシューティカルス・インコーポレーテッド トランスフォーミング成長因子−β発現のアンチセンスオリゴヌクレオチド調節
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
CA2494367A1 (en) * 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
WO2005019422A2 (en) * 2003-08-13 2005-03-03 The Board Of Trustees Of The University Of Illinois Silencing of tgf-beta receptor type ii expression by sirna
US7462185B1 (en) * 2004-12-23 2008-12-09 Cardican Inc. Intravascular stapling tool
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Similar Documents

Publication Publication Date Title
JP2009513663A5 (enExample)
Ogawa et al. The role of leukotrienes in airway inflammation
Brown et al. The microbiota protects from viral-induced neurologic damage through microglia-intrinsic TLR signaling
Ghasemi et al. The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Stone et al. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Pietropaoli et al. Occurrence of spontaneous periodontal disease in the SAMP1/YitFc murine model of Crohn disease
Chang et al. Odontogenic infection involving the secondary fascial space in diabetic and non-diabetic patients: a clinical comparative study
JP2014528474A5 (enExample)
Haussmann et al. Minireview: Lithium: A therapeutic option in Alzheimer’s disease and its prodromal stages?
FI2839836T4 (fi) Probiootit käytettäväksi vähennettäessä hengityselintaudin oireita
JP2023113650A5 (enExample)
JP2009513660A5 (enExample)
Anderson et al. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson’s disease
Domm et al. Affect of early life oxygen exposure on proper lung development and response to respiratory viral infections
JP2011511006A5 (ja) 肺病態に対する医薬組成物
JP2012502909A5 (enExample)
Gan et al. Modulation of the immunity and inflammation by autophagy
Liu et al. Are dexmedetomidine and olanzapine suitable to control delirium in critically ill elderly patients? A retrospective cohort study
JP2012527438A5 (enExample)
Amano et al. Opposite associations between the rs3845446 single-nucleotide polymorphism of the CACNA1E gene and postoperative pain-related phenotypes in gastrointestinal surgery versus previously reported orthognathic surgery
Xu et al. Traversing the epigenetic landscape: DNA methylation from retina to brain in development and disease
JP2009523456A5 (enExample)
CN109069471A (zh) 用于治疗流感病毒的组合物和方法
RU2011148558A (ru) Способ диагностики и лечения хронического аденоидита у детей
Chen et al. Effect of cyclosporine‐A on orthodontic tooth movement in rats